RESUMO
Adenovirus vectors have great potential in cancer gene therapy. Targeting of cancer-testis (CT) antigens, which are specifically presented at the surface of tumor cells by human leukocyte antigen (HLA) class I molecules, is an attractive option. In this study, a single-chain T-cell receptor (scTCR) directed against the CT antigen melanoma-associated antigen (MAGE)-A1 in complex with the HLA class I molecule of haplotype HLA-A1 is fused with the C terminus of the adenovirus minor capsid protein IX. Propagation of a protein-IX (pIX)-gene-deleted human adenovirus 5 (HAdV-5) vector on cells that constitutively express the pIXscTCR fusion protein yielded viral particles with the pIXscTCR fusion protein incorporated in their capsid. Generated particles specifically transduced melanoma cell lines expressing the HLA-A1/MAGE-A1 target complex with at least 10-fold higher efficiency than control viruses. Whereas loading of HLA-A1-positive cells with MAGE-A1 peptides leads to enhanced transduction of the cells, the efficiency of virus transduction is strongly reduced if the HLA-A1 molecules are not accessible at the target cell. Taken together, these data provide proof of principle that pIXscTCR fusions can be used to target HAdV-5 vectors to tumor cells expressing intracellular CT antigens.
Assuntos
Adenoviridae/genética , Terapia Genética/métodos , Vetores Genéticos/administração & dosagem , Melanoma/terapia , Transdução Genética/métodos , Apresentação de Antígeno , Antígenos de Neoplasias/imunologia , Proteínas do Capsídeo/genética , Linhagem Celular Tumoral , Citotoxicidade Imunológica , Citometria de Fluxo , Marcação de Genes , Engenharia Genética , Vetores Genéticos/genética , Antígeno HLA-A1/imunologia , Humanos , Masculino , Melanoma/imunologia , Melanoma/metabolismo , Antígenos Específicos de Melanoma , Proteínas de Neoplasias/imunologia , Receptores de Antígenos de Linfócitos T/genéticaRESUMO
Progressive multifocal leukoencephalopathy (PML) is a deadly brain disease caused by the polyomavirus JC (JCV). The aim of this study is to develop 'designer T cells' armed with anti-JCV TCR-based chimeric immune receptors (CIRs) by gene modification for PML immunotherapy. Two T cell lines specific to two dominant CTL epitopes derived from JCV VP1 protein (termed p36 and p100) from an HLA-A0201+ PML survivor were generated for TCR cloning. Two distinct dominant TCR alpha chains (Valpha6 and Valpha12) and a unique TCR beta chain (Vbeta5.1) were cloned from the p36-specific cell line, while only one alpha (Valpha8.6) and one beta (Vbeta2) chains were dominant in the p100-specific line. Retroviral constructs encoding CIRs were created with the extracellular domains of TCR alpha and beta chains fused to the transmembrane and cytoplasmic portions of CD3zeta (ValphaCalphaCD3zeta or VbetaCbetaCD3zeta). Cellular expression and screening for binding specific peptide-HLA-A0201 tetramer confirmed the reactivity of the p100 TCRalphabeta and of one of the two pairs of p36 TCRalphabeta (Valpha12 and Vbeta5.1). Functional tests confirmed CIR-expressing T cells secreted cytokines and expressed potent cytotoxicity on contact with A0201+ B-lymphoblastoid line loaded with peptides and/or with HLA-A0201+ cells expressing native JCV VP1 protein. In conclusion, anti-JCV designer T cells were generated.
Assuntos
Imunoterapia , Vírus JC/imunologia , Leucoencefalopatia Multifocal Progressiva/terapia , Receptores de Antígenos de Linfócitos T alfa-beta/imunologia , Proteínas Recombinantes de Fusão/imunologia , Reações Antígeno-Anticorpo , Linhagem Celular , Proliferação de Células/efeitos dos fármacos , Clonagem Molecular , Citocinas/biossíntese , Citocinas/metabolismo , Testes Imunológicos de Citotoxicidade , Progressão da Doença , Humanos , Peptídeos/farmacologia , Receptores de Antígenos de Linfócitos T alfa-beta/genética , Proteínas Recombinantes de Fusão/genética , Sensibilidade e Especificidade , Linfócitos T/imunologia , Proteínas Virais/imunologiaRESUMO
We have designed a transgene that encodes a scFv(G250) chimeric receptor, which is specific for carboxyanhydrase IX (G250-ligand, G250L), a molecule overexpressed by renal cell cancer (RCC). Retroviral transduction of this transgene into primary human T lymphocytes confers these cells with specific functional responses towards G250L-positive RCC cells. In preparation of a clinical phase (I/II) study in RCC patients, we set up a protocol for gene transduction and expansion of primary human T cells. For this purpose, we directly compared two packaging cell lines, that is, the GALV-pseudotyped MLV producing cell line PG13, and the MLV-A-producing cell line Phi-NX-Ampho (a.k.a. Phoenix-A). We generated and characterized stable scFv(G250)-positive clones of both PG13 and Phoenix cells and optimized the retrovirus production conditions. Transductions of primary human T cells yielded 30-60% scFv(G250)+ T cells using PG13-derived retrovirus versus up to 90% scFv(G250)+ T cells using Phoenix-derived retrovirus. The median number of transgene integrations per scFv(G250)+ T cell differed only 1.5-fold as determined by real-time PCR (mean number of integrations per T cell 2.6 and 3.7 for PG13 and Phoenix-based transductions, respectively). In addition, T cells transduced with Phoenix-derived retrovirus showed, on a per cell basis, 10-30% higher levels of scFv(G250)-mediated TNFalpha production and cytolysis of G250L+ RCC cells than T cells transduced with PG13-derived retrovirus. The improved functional transduction efficiency together with a limited increase in the number of integrations per recipient cell, made us select Phoenix clone 58 for our clinical immunogene therapy study.
Assuntos
Antígenos de Neoplasias/genética , Anidrases Carbônicas/genética , Região Variável de Imunoglobulina/genética , Neoplasias Renais/terapia , Receptores Imunológicos/genética , Linfócitos T , Transdução Genética/métodos , Montagem de Vírus , Anidrase Carbônica IX , Linhagem Celular , Células Cultivadas , Terapia Combinada , Citotoxicidade Imunológica , Terapia Genética/métodos , Humanos , Imunoterapia Adotiva/métodos , Retroviridae/genética , Anticorpos de Cadeia Única , Linfócitos T/imunologia , Linfócitos T/transplanteRESUMO
Adoptive transfer of antigen-specific T cells has recently shown therapeutic successes in the treatment of viral infections and tumors. T cells specific for the antigen of interest can be generated in vitro, and adoptively transferred back to provide patients with large numbers of immune-competent T cells. Adoptive T cell therapy, however, is a patient-tailored treatment that unfortunately is not universally applicable to treat viral infections and tumors. We and others have demonstrated that the transfer of genes encoding antigen-specific receptors into T cells (i.e., genetic retargeting) represents an attractive alternative to induce antigen-specific immunity. Currently, we evaluate this concept in a clinical protocol to treat patients with metastatic renal cell cancer (RCC) using autologous RCC-specific gene-modified T lymphocytes.
Assuntos
Carcinoma de Células Renais/terapia , Fragmentos de Imunoglobulinas/genética , Imunoterapia Adotiva/métodos , Linfócitos T Citotóxicos/transplante , Animais , Anticorpos Monoclonais/imunologia , Anticorpos Monoclonais/uso terapêutico , Antígenos de Neoplasias/imunologia , Ensaios Clínicos como Assunto , Testes Imunológicos de Citotoxicidade , Citometria de Fluxo , Humanos , Fragmentos de Imunoglobulinas/imunologia , Imunoterapia Adotiva/efeitos adversos , Interferon gama/metabolismo , Fígado/fisiopatologia , Contagem de Linfócitos , Camundongos , Receptores de Antígenos de Linfócitos T/genética , Receptores de Antígenos de Linfócitos T/imunologia , Linfócitos T Citotóxicos/citologia , Linfócitos T Citotóxicos/imunologia , Transdução Genética , Transplante Autólogo/imunologia , Resultado do Tratamento , Ensaios Antitumorais Modelo de XenoenxertoRESUMO
We identified a tumor-associated cytotoxic T lymphocyte (CTL) epitope derived from the widely expressed human MDM2 oncoprotein and were able to bypass self-tolerance to this tumor antigen in HLA-A*0201 (A2.1) transgenic mice and by generating A2.1-negative, allo-A2.1-restricted human T lymphocytes. A broad range of malignant, as opposed to nontransformed cells, were killed by high-avidity transgenic mouse and allogeneic human CTLs specific for the A2.1-presented MDM2 epitope. Whereas the self-A2.1-restricted human T cell repertoire gave rise only to low-avidity CTLs unable to recognize the natural MDM2 peptide, human A2.1+ T lymphocytes were turned into efficient MDM2-specific CTLs upon expression of wild-type and partially humanized high-affinity T cell antigen receptor (TCR) genes derived from the transgenic mice. These results demonstrate that TCR gene transfer can be used to circumvent self-tolerance of autologous T lymphocytes to universal tumor antigens and thus provide the basis for a TCR gene transfer-based broad-spectrum immunotherapy of malignant disease.
Assuntos
Genes Codificadores dos Receptores de Linfócitos T , Terapia Genética , Neoplasias/imunologia , Proteínas Nucleares , Proteínas Proto-Oncogênicas/imunologia , Tolerância a Antígenos Próprios , Linfócitos T Citotóxicos/imunologia , Animais , Antígenos de Neoplasias/imunologia , Linhagem Celular , Testes Imunológicos de Citotoxicidade , Epitopos de Linfócito T/imunologia , Antígeno HLA-A2/genética , Humanos , Imunoterapia Adotiva , Leucemia/imunologia , Leucemia/terapia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Neoplasias/terapia , Proteínas Proto-Oncogênicas c-mdm2 , Transdução Genética , Células Tumorais CultivadasRESUMO
In contrast to murine leukaemia virus (MLV)-derived vector systems, vector particles derived from the avian spleen necrosis virus (SNV) have been successfully targeted to subsets of human cells by envelope modification with antibody fragments (scFv). However, an in vivo application of the SNV vector system in gene transfer protocols is hampered by its lack of resistance against human complement. To overcome this limitation we established pseudotyping of MLV vector particles produced in human packaging cell lines with the SNV envelope (Env) protein. Three variants of SNV Env proteins differing in the length of their cytoplasmic domains were all efficiently incorporated into MLV core particles. These pseudotype particles infected the SNV permissive cell line D17 at titers of up to 10(5) IU/ml. A stable packaging cell line (MS4) of human origin released MLV(SNV) pseudotype vectors that were resistant against human complement inactivation. To redirect their tropism to human T cells, MS4 cells were transfected with the expression gene encoding the scFv 7A5 in fusion with the transmembrane domain (TM) of the SNV Env protein, previously shown to retarget SNV vector particles to human lymphocytes. MLV(SNV-7A5)-vector particles released from these cells were selectively infectious for human T cell lines. The data provide a proof of principle for targeting MLV-derived vectors to subpopulations of human cells through pseudotyping with SNV targeting envelopes.
Assuntos
Terapia Genética/métodos , Vetores Genéticos/administração & dosagem , Retroviridae/genética , Transfecção/métodos , Animais , Linhagem Celular , Cães , Engenharia Genética/métodos , Humanos , Vírus da Leucemia Murina/genéticaRESUMO
The clinical benefit of adoptive transfer of MHC-restricted cytotoxic T lymphocytes(CTL) for the treatment of cancer is hampered by the low success rate to generate antitumor CTLs. To bypass the need for tumor-specific CTL, we developed a strategy that allows for grafting of human T lymphocytes with MHC-restricted antigen specificity using in vitro selected human Fab fragments fused to the Fc(epsilon)RI-gamma signaling molecule. Retroviral introduction of a Fab-based chimeric receptor specific for MAGE-A1/HLA-A1 into primary human T lymphocytes resulted in binding of relevant peptide/MHC complexes. Transduced T lymphocytes responded to native MAGE-A1/HLA-A1POS target cells by specific cytokine production and cytolysis. Therefore, peptide/MHC-specific Fab fragments represent new alternatives to TCR to confer human T lymphocytes with tumor specificity, which provides a promising rationale for developing immunogene therapies.
Assuntos
Terapia Genética/métodos , Fragmentos Fab das Imunoglobulinas/genética , Imunoterapia Adotiva/métodos , Melanoma/terapia , Receptores Imunológicos/genética , Antígenos de Neoplasias , Epitopos , Vetores Genéticos/administração & dosagem , Antígeno HLA-A1/imunologia , Humanos , Fragmentos Fab das Imunoglobulinas/metabolismo , Melanoma/imunologia , Antígenos Específicos de Melanoma , Proteínas de Neoplasias/imunologia , Biblioteca de Peptídeos , Retroviridae/genética , Linfócitos T Citotóxicos/imunologia , Transdução Genética , Células Tumorais CultivadasRESUMO
Primary human activated T lymphocytes were genetically grafted with chimeric T cell receptors (TCR). Three domain single chain (sc-) TCR as well as two chain (tc-) TCR gene constructs were derived from the melanoma-specific cytotoxic human T cell (CTL) clone 82/30, and linked to the CD3-zeta signaling element. Chimeric TCR alpha and beta receptor genes were structurally designed to prevent pairing with endogenous TCR alpha and beta chains in order to prevent the generation of unpredictable immune specificities. After transduction of polyclonally activated human peripheral blood lymphocytes with retroviral vectors harboring the chimeric receptor genes, genetically engineered cells specifically recognized and responded to MAGE-A1POS/HLA-A1POS cells. Importantly, each type of transduced T lymphocytes that bound specifically to peptide/MHC complexes also showed specific antitumor reactivity as well as lymphokine production. Genetically engineered primary human T lymphocytes expressing chimeric sc- or tc-TCR therefore hold promise for disease-specific therapies.
Assuntos
Técnicas de Transferência de Genes , Terapia Genética/métodos , Receptores de Antígenos de Linfócitos T alfa-beta/genética , Linfócitos T/metabolismo , Quimera , Células Clonais , Vetores Genéticos , Fator Estimulador de Colônias de Granulócitos e Macrófagos/biossíntese , Humanos , Interferon gama/biossíntese , Melanoma/imunologia , Engenharia de Proteínas , Retroviridae , Linfócitos T/imunologia , Fator de Necrose Tumoral alfa/biossínteseRESUMO
Recombinant T-cell receptors with antibody-like specificity for tumor-associated antigens are successfully used to direct the cytolytic activity of T cells toward tumor cells. Clinical application, however, needs to comply with the low immunogenicity of the recombinant receptor, efficient gene transfer into peripheral blood T cells, and enrichment of receptor-grafted cells. Here, we address these issues and describe an entirely humanized immune receptor for use in adoptive immunotherapy of colorectal carcinoma. The receptor consists of a single-chain antibody (scFv) binding domain specific for carcinoembryonic antigen (CEA), the IgG hinge and CH2/CH3 (Fc) joining region, and the transmembrane and intracellular CD3 zeta signaling chain. To express the receptor in peripheral blood T cells, both GALV envelope and MuLV 4070A pseudotyped retrovirus turned out to be equally efficient, with transduction efficiencies of about 5% to 40%, depending on the lymphocyte donor. Furthermore, receptor-grafted T cells could be 2- to 6-fold enriched by magnetic activated cell sorting, utilizing an antibody directed to the extracellular IgG domain of the receptor. Upon co-culture with CEA(+) tumor cells, receptor-grafted T cells are specifically and efficiently activated to cytolysis and IFN-gamma secretion, demonstrating their feasibility for the adoptive immunotherapy of CEA(+) carcinomas.
Assuntos
Antígeno Carcinoembrionário/imunologia , Proteínas de Transporte/imunologia , Neoplasias do Colo/imunologia , Proteínas de Membrana/imunologia , Complexo Receptor-CD3 de Antígeno de Linfócitos T/imunologia , Receptores de Antígenos de Linfócitos T/imunologia , Receptores de Superfície Celular , Linfócitos T/imunologia , Especificidade de Anticorpos , Antígeno Carcinoembrionário/biossíntese , Proteínas de Transporte/biossíntese , Proteínas de Transporte/genética , Neoplasias do Colo/terapia , Reações Cruzadas , Citotoxicidade Imunológica , Epitopos de Linfócito T/imunologia , Técnicas de Transferência de Genes , Humanos , Fragmentos de Imunoglobulinas/genética , Fragmentos de Imunoglobulinas/imunologia , Separação Imunomagnética , Imunoterapia Adotiva/métodos , Vírus da Leucemia do Macaco Gibão/genética , Vírus da Leucemia Murina/genética , Ativação Linfocitária , Proteínas de Membrana/biossíntese , Proteínas de Membrana/genética , Estrutura Terciária de Proteína , Complexo Receptor-CD3 de Antígeno de Linfócitos T/genética , Receptores de Antígenos de Linfócitos T/biossíntese , Receptores de Antígenos de Linfócitos T/genética , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/imunologia , Proteínas Recombinantes/genética , Proteínas Recombinantes/imunologia , Transdução de Sinais/imunologia , Linfócitos T/metabolismo , Linfócitos T/virologiaRESUMO
Adhesion and accessory molecules play a critical role in T-cell activation and effector function in general and in tumor cell recognition and lysis in particular. We investigated the contribution of CD2, CD3, CD11a/CD18, CD54 and CD58 molecules in T lymphocyte-tumor cell interactions mediated by chimeric immunoglobulin receptors. The chimeric receptor is composed of a single chain antibody binding site and a gamma-chain signal transducing molecule (scFv/gamma). T lymphocytes expressing such scFv/gamma receptors recognize the G250 Ag on renal cell carcinoma (RCC) in an major histocompatibility complex (MHC)-unrestricted manner and exert RCC selective cytolysis. A coregulatory role for CD2, CD3 and CD11a/CD18 molecules in scFv/gamma-mediated cytolysis was demonstrated using monoclonal antibody (MAb)-induced inhibition of scFv/gamma-mediated cytolysis. The inhibition of lysis was not due to inhibition of cytotoxic T lymphocyte (CTL)-target cell conjugation but rather to a post-conjugate signaling event. Binding of CD54 and CD58 MAbs to the RCC did not inhibit cytolysis of RCC cells that expressed high levels of both CD54 and the G250 antigen (Ag) (A75), whereas cytolysis of RCC expressing intermediate levels of CD54 and G250 Ag (SK-RC-17 cl.4) was partly inhibited by the CD54 MAb. Binding of low concentrations of G250 MAb to RCC (A75) rendered these cells sensitive to CD54 MAb inhibition, demonstrating a direct functional relation between G250 Ag expression level and adhesion molecules. Taken together, our findings indicate a coregulatory role for CD2, CD3 and CD11a/CD18 molecules in the scFv/gamma-mediated cytolysis of tumor cells and show that the requirement of CD11a/CD18-CD54 interactions is dependent on the level of free Ag. This make these gene-transduced T lymphocytes attractive tools for adoptive immunogene therapy of cancer.
Assuntos
Antígenos CD/imunologia , Antígenos de Neoplasias/imunologia , Carcinoma de Células Renais/imunologia , Fragmentos de Imunoglobulinas/imunologia , Receptores de Antígenos de Linfócitos T gama-delta/imunologia , Proteínas Recombinantes de Fusão/imunologia , Linfócitos T Citotóxicos/imunologia , Anticorpos Monoclonais/farmacologia , Antígenos CD11/imunologia , Antígenos CD18/imunologia , Antígenos CD2/imunologia , Complexo CD3/imunologia , Antígenos CD58/imunologia , Citotoxicidade Imunológica , Humanos , Molécula 1 de Adesão Intercelular/imunologia , Melanoma/imunologia , Transfecção , Células Tumorais CultivadasRESUMO
Genetic engineering of T lymphocytes for adoptive clinical immunotherapy calls for efficient gene transduction methods. Therefore, a transient retroviral gene transduction system 'STITCH' was developed comprising pSTITCH retroviral vector encoding the transgene, plasmids encoding Moloney murine leukemia virus gag/pol and gibbon ape leukemia virus envelope, and the human kidney cell line 293T as a packaging line. Cotransfection of retroviral vector and packaging plasmids in 293T cells results in the production of GALV env pseudotyped viral particles with a titer of 10(7) infectious units per milliliter. The 'STITCH' gene transduction system efficiently transduces genes into activated human T lymphocytes derived from healthy donors and cancer patients. The efficacy of gene transduction is donor-independent. A direct application of the 'STITCH' gene transduction system is the genetic engineering of activated human T lymphocytes to induce expression of antibody based chimeric receptors in their membrane. Introduction of these chimeric receptors into activated human T lymphocytes graft these cells with specificity for, for example, renal cell carcinoma. In order to study the effect of the chimeric receptor gene structure on the processes ultimately leading to functional membrane expression, we designed a number of different chimeric receptor gene structures and subsequently compared their membrane expression on 293T cells and activated human T lymphocytes. Distinct membrane expression densities were observed on 293T cells and human T lymphocytes for the different chimeric receptor gene constructs. Gene transduction of activated human T lymphocytes with four out of five chimeric receptor gene constructs resulted in functional expression of chimeric receptor as demonstrated by specific recognition and cytolysis of renal cell carcinoma.
Assuntos
Terapia Genética/métodos , Vetores Genéticos , Linfócitos do Interstício Tumoral/metabolismo , Receptores Imunológicos/genética , Retroviridae/genética , Carcinoma de Células Renais/imunologia , Carcinoma de Células Renais/terapia , Membrana Celular/metabolismo , Expressão Gênica , Humanos , Neoplasias Renais/imunologia , Neoplasias Renais/terapia , Receptores de Antígenos de Linfócitos T/genética , Proteínas Recombinantes de Fusão/genética , Transdução Genética , Células Tumorais CultivadasAssuntos
Antígenos CD4/genética , Carcinoma de Células Renais/imunologia , Carcinoma de Células Renais/terapia , Terapia Genética , Região Variável de Imunoglobulina/genética , Neoplasias Renais/imunologia , Neoplasias Renais/terapia , Transfusão de Linfócitos , Linfócitos T/imunologia , Antígenos CD4/biossíntese , Terapia Genética/efeitos adversos , Humanos , Região Variável de Imunoglobulina/biossíntese , Ativação Linfocitária , Transfusão de Linfócitos/efeitos adversos , Proteínas Recombinantes de Fusão/biossíntese , Transfecção/métodos , Transplante AutólogoRESUMO
To enable construction of CTL with known predefined Ab specificity for adoptive immunotherapy, we constructed a chimeric scFv/gamma gene composed of the variable regions of a mAb joined to the Fc(epsilon)RI signaling receptor gamma-chain of mast cells. Introduction of this chimeric receptor into CTL rendered these lymphocytes specific for renal cell carcinoma. This approach combines the specificity of tumor-selective Abs with the efficacy of CTL to destroy tumor cells. We not only demonstrated that the transduced CTL functionally express the scFv/gamma receptor for a prolonged period of time (4.5 mo of in vitro culture), but also showed high levels of Ab-dictated lysis of renal cell carcinoma similar to that of normal CTL, and importantly, we demonstrated that these CTL can recycle their lytic activity. Moreover, these scFv/gamma-expressing T lymphocytes produce cytokines upon stimulation with the relevant target cell. These results together with the donor independence of our gene transduction protocol demonstrate the feasibility of redirecting T lymphocytes for cancer treatment.